(function() { var x="https://ads.ehealthcaresolutions.com/c/?"+Math.random()*1e16; var y=document.createElement("script");y.type="text/javascript";y.async=true;y.src=x; var z=document.getElementsByTagName("script")[0]; z.parentNode.insertBefore(y, z); })();
Monday , June 18 2018
Home / Letter From The Editor / GLP-1 Editor’s Note:

GLP-1 Editor’s Note:

Jun 14, 2011

This week I had a chance to interview Dr. Vivian Fonseca on the use of GLP-1 agonists, and he shared his thoughts on why these medications are a logical choice. He also gave us a little information on a study using GLP-1 agonists with insulin, and why he thinks the FDA should approve the combination.

Our GLP-1 Case Study this week targets a 25-year-old Hispanic woman with a 5-year history of type 2 diabetes, who has not been able to get her A1c under control, and Louis Kuritzky, MD, Clinical Assistant Professor, University of Florida, has a short interactive video on the potential for tissue damage before and after diagnosis of diabetes, and the protective benefits of early and effective intervention.